Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Other COVID-19 Resources

Safety of COVID-19 vaccines – April updates

ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines

EMA recommends authorisation of COVID-19 medicine Evusheld

EMA recommends authorisation of booster doses of Comirnaty from 12 years of age

EMA recommends approval of Spikevax…

Read more

Kite and Gilead @EHA25 Virtual

We are proud to support the first ever EHA25 Virtual congress. Please join us & leading experts to learn about the latest in cell therapies and COVID-19.

Read more

Joint Membership

This membership is designed for scientific researchers and physicians from multiple national societies who specialize or are interested in hematology. The main aim is to increase the cooperation in various areas and therefore strengthen hematology at the European level.

Read more

Chairs and Members

Chair:
Francesco Buccisano, Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy (2021-2024)

Co-Chair:
Sylvie Freeman, Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK (2021-2024)

SWG Executive Board members and terms:

Torsten Haferlach, MLL Munich Leukemia Laboratory, Munich, Germany…

Read more